Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials.
Dijian ShenRunzhe ChenQing WuYongling JiBerend J van der WilkEmerson Y ChenQixun ChenMing ChenPublished in: Journal of gastrointestinal oncology (2024)
Esophagectomy was safe after the addition of the PD-1 inhibitor to preoperative CT or CRT in ESCC neoadjuvant therapies. Follow-up and the exploratory endpoints, including biomarkers analyses, are ongoing.
Keyphrases
- squamous cell
- locally advanced
- phase ii
- clinical trial
- rectal cancer
- open label
- squamous cell carcinoma
- radiation therapy
- robot assisted
- double blind
- phase iii
- computed tomography
- placebo controlled
- image quality
- patients undergoing
- study protocol
- dual energy
- contrast enhanced
- lymph node
- magnetic resonance imaging
- randomized controlled trial
- positron emission tomography
- papillary thyroid
- young adults
- left ventricular
- cardiac resynchronization therapy